Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Carbogen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Carbogen. Displaying page 1 of 1.
    EudraCT Number: 2011-001403-12 Sponsor Protocol Number: CARDIF Start Date*: 2012-03-14
    Sponsor Name:Charite Universitaetsmedizin Berlin
    Full Title: Carbon Dioxide for the Treatment of Febrile Seizures
    Medical condition: febrile seizures
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005318-12 Sponsor Protocol Number: NCTU:CONCEPT1 Start Date*: 2012-04-13
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Phase 1 study of use of 5% Carbogen in treatment of paediatric non-convulsive status epilepticus
    Medical condition: Paediatric non-convulsive status epilepticus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10057769 Nonconvulsive status epilepticus LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021886-63 Sponsor Protocol Number: RD2010-48 Start Date*: 2011-07-14
    Sponsor Name:East and North Hertfordshire NHS Trust [...]
    1. East and North Hertfordshire NHS Trust
    2.
    Full Title: A trial of Prostate Radiotherapy in Conjunction with Carbogen and Nicotinamide (PROCON)
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004149-19 Sponsor Protocol Number: BO42777 Start Date*: 2022-05-24
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE I...
    Medical condition: Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004864 10084713 Tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001294-25 Sponsor Protocol Number: IPOXVILI Start Date*: 2018-07-26
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Regional Hypo-perfusion as metabolic raiser of ventilator-induced lung injury (VILI): pilot clinica trial
    Medical condition: Severe Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038651 Respiration failure LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001053 Acute respiratory failure PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Nov 02 12:47:38 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA